MX2022010201A - Uso de analogos de ciclosporina para el tratamiento de la fibrosis. - Google Patents

Uso de analogos de ciclosporina para el tratamiento de la fibrosis.

Info

Publication number
MX2022010201A
MX2022010201A MX2022010201A MX2022010201A MX2022010201A MX 2022010201 A MX2022010201 A MX 2022010201A MX 2022010201 A MX2022010201 A MX 2022010201A MX 2022010201 A MX2022010201 A MX 2022010201A MX 2022010201 A MX2022010201 A MX 2022010201A
Authority
MX
Mexico
Prior art keywords
treating fibrosis
cyclosporine
cyclosporine analogues
crv431
stereoisomer
Prior art date
Application number
MX2022010201A
Other languages
English (en)
Inventor
Daren R Ure
Daniel J Trepanier
Patrick R Mayo
Robert T Foster
Original Assignee
Hepion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hepion Pharmaceuticals Inc filed Critical Hepion Pharmaceuticals Inc
Publication of MX2022010201A publication Critical patent/MX2022010201A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se divulgan métodos, composiciones y kits adecuados para su uso en la prevención, el tratamiento o la reversión de la fibrosis. Los métodos comprenden la administración a un sujeto que lo necesite de una composición que comprende un análogo de ciclosporina (por ejemplo, CRV431), o una sal, solvato y estereoisómero farmacéuticamente aceptable. Las composiciones y los kits comprenden un análogo de ciclosporina (por ejemplo, CRV431), o una sal, solvato, estereoisómero farmacéuticamente aceptable del mismo.
MX2022010201A 2020-02-19 2021-02-19 Uso de analogos de ciclosporina para el tratamiento de la fibrosis. MX2022010201A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062978526P 2020-02-19 2020-02-19
US202062981383P 2020-02-25 2020-02-25
PCT/US2021/018639 WO2021168161A1 (en) 2020-02-19 2021-02-19 Use of cyclosporine analogues for treating fibrosis

Publications (1)

Publication Number Publication Date
MX2022010201A true MX2022010201A (es) 2022-09-19

Family

ID=75108767

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010201A MX2022010201A (es) 2020-02-19 2021-02-19 Uso de analogos de ciclosporina para el tratamiento de la fibrosis.

Country Status (12)

Country Link
US (1) US20210260153A1 (es)
EP (1) EP4106791A1 (es)
JP (1) JP2023514837A (es)
KR (1) KR20220143059A (es)
CN (1) CN115427060A (es)
AU (1) AU2021224676A1 (es)
BR (1) BR112022016522A2 (es)
CA (1) CA3171882A1 (es)
IL (1) IL295452A (es)
MX (1) MX2022010201A (es)
TW (1) TW202143994A (es)
WO (1) WO2021168161A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372807A (en) 1990-05-14 1994-12-13 University Of Medicine And Dentistry Of New Jersey Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use
US20020006901A1 (en) * 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
CN102439456B (zh) * 2009-03-19 2016-11-02 昂热大学 用于评估肝纤维化进展的非侵入方法
WO2018106928A1 (en) * 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
US20180296588A1 (en) * 2017-04-14 2018-10-18 Contravir Pharmaceuticals, Inc. Combination therapy for treating viral infections
CA3120015A1 (en) 2018-11-26 2020-06-04 Hepion Pharmaceuticals, Inc. Pharmaceutical formulations of cyclosporine analogs

Also Published As

Publication number Publication date
KR20220143059A (ko) 2022-10-24
IL295452A (en) 2022-10-01
BR112022016522A2 (pt) 2022-10-11
US20210260153A1 (en) 2021-08-26
CA3171882A1 (en) 2021-08-26
EP4106791A1 (en) 2022-12-28
TW202143994A (zh) 2021-12-01
WO2021168161A1 (en) 2021-08-26
AU2021224676A1 (en) 2022-09-08
CN115427060A (zh) 2022-12-02
JP2023514837A (ja) 2023-04-11

Similar Documents

Publication Publication Date Title
BRPI0510110A (pt) método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica
JOP20220179A1 (ar) N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها
MXPA05004778A (es) Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas.
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
PH12019550263A1 (en) A Pharmaceutical Composition for Anaemia
KR102375262B9 (ko) Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물
MX2021013582A (es) Composiciones que comprenden agentes biologicamente activos y sales biliares.
EA200870368A1 (ru) Антибиотические композиции с модифицированным высвобождением и способ их получения
WO2020086747A3 (en) Ssao inhibitors and uses thereof
GEP20247585B (en) Furoindazole derivatives
MX2023011464A (es) Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7).
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
EP4397375A3 (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
MX2015000884A (es) Composicion odontologica de papaina en gel para el tratamiento atraumatico de caries y metodo para prepararla.
PH12021551086A1 (en) Pharmaceutical formulations of cyclosporine analogs
WO2020160493A3 (en) Compounds, compositions and methods for treatment of myopia
WO2022216552A3 (en) Novel hepatoselective polyadenylating polymerases inhibitors and their method of use
MX2022010201A (es) Uso de analogos de ciclosporina para el tratamiento de la fibrosis.
AU2018260628A1 (en) Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
MX2022010454A (es) Uso de analogos de ciclosporina para el tratamiento contra el cancer.
MY186286A (en) A pharmaceutical composition for improving or preventing progression of chronic kidney disease
WO2021216450A8 (en) Opioid antagonist formulations